Last reviewed · How we verify
A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in South Africa
Approximately 42 HIV-negative women, aged \>18 and \< 50, will be enrolled in this study. Each volunteer will have a 2:1 chance of receiving Dapivirine Gel-002 versus placebo. The volunteers will receive investigational product for a total of 42 days.
Details
| Lead sponsor | International Partnership for Microbicides, Inc. |
|---|---|
| Phase | PHASE1, PHASE2 |
| Status | WITHDRAWN |
Conditions
- HIV Infections
Interventions
- dapivirine (TMC120) vaginal gel